Stockreport

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal ...

Lucid Diagnostics Inc.  (LUCD) 
PDF Publication further strengthens EsoGuard's clinical data supporting ongoing engagement to secure commercial and Medicare payor coverage NEW YORK May 2, 2024 /PRNewswi [Read more]